Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005;23:4215-4224.
Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411:1017-1021.
Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006;9:23-32.
Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25-35.
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925-36.
Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209-219.
Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC). J Clin Oncol. 2017;35(suppl). Abstract 1038.
Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638-3646.
Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2-negative metastatic breast cancer. Clin Cancer Res. 2017;23:5218-5224.
Sledge GWJr, Toi M, Neven P et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR1/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875-2884.
Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018 Jun 3:JCO2018789909.
Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018. pii:S1470-2045(18)30292-4.
Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol. 2016;34:3069-103.
Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018. doi:0.1093/annonc/mdy192
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast cancer. Version 1.2018. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed August 25 2018.
Finn R, Jiang Y, Rugo H, et al. Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib with letrozole compared with placebo plus letrozole in postmenopausal women with ER+/HER2-advanced breast cancer. Ann Oncol. 2016;27:(suppl 6) Abstract LBA15.
Finn RS, Lui Y, Martin M, et al. Comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study. Presented at: San Antonio Breast Cancer Symposium 2017; San Antonio, TX; December 5-9, 2017. P2-09-10.
Christofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor- positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-439.
Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34:2961-2968.
Hortobagyi GN, Stemmer SM, Campone M, et al. First-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: efficacy by baseline circulating tumor DNA alterations in MONALEESA-2. Paper presented at San Antonio Breast Cancer Symposium, 2017. Cancer Res. 2018;78(suppl). Abstract PD4-06.
Shah M, Nunes MR, Stearns V. CDK 4/6 inhibitors: game changers in the management of hormone receptor-positive advanced breast cancer? Oncology (Williston Park). 2018;32:216-22.
Ma CX, Dickler M. Treatment approach to metastatic hormone receptor-positive, HER2-negative breast cancer: endocrine therapy. UpToDate. https://www.uptodate.com/contents/treatment-approach-to-metastatic-hormone-receptor-positive-her2-negative-breast-cancer-endocrine-therapy/print Accessed August 25, 2018.
Jeselsohn R, Buchwalter G, De Angelis C, et al. ESR1 mutations -- a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12:573-583.
Klijn JG, Beex LV, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000;92:903-911.
Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29:4452-4461.
Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2017. [Epub ahead of print]
Matikas A, Foukakis T, Bergh J. Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: a tale of imprecision medicine. Crit Rev Oncol Hematol. 2017;114:91-101.
Gyanchandani R, Kota KJ, Jonnalagadda AR, et al. Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. Oncotarget. 2016;8:66901-66911.
Dixon JM. Endocrine resistance in breast cancer. N J Sci. 2014;2014:1-27.
Brufsky AM, Dickler MN. Estrogen receptor-positive breast cancer: exploiting signaling pathways implicated in endocrine resistance. Oncologist. 2018;23:1-12.
Guarducci C, Bonechi M, Boccalini G, et al. Mechanisms of resistance to CDK 4/6 inhibitors in breast cancer and potential biomarkers of response. Breast Care. 2017;12:304-308.
Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-247.
Han HS, Magliocco AM. Molecular testing and the pathologist's role in clinical trials of breast cancer. Clin Breast Cancer. 2016;16:166-179.
Abbosh C, Swanton C, Birkbak NJ. Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer. Ann Oncol. 2018;29:535-537.
Turner NC, O'Leary B, Cutts R, et al. Genetic landscape of resistance to CDK 4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant. J Clin Oncol. 2018;36:(suppl). Abstract 1001.
Yang C, Li Z, Bhatt T, Dickler M, et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK 4/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2017;36:2255-2264.
Martin L-A, Pancholi S, Ribas R, et al. Resistance to palbociclib depends on multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium, 2016. Cancer Res. 2017;77(suppl). Abstract P3-03-09.
Lenihan C, Bouchekioua-Bouzaghou K, Abdulghani R, et al. CDK 4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium, 2016. Cancer Res. 2017;77(suppl). Abstract P3-03-12.
Ma CX, Gao F, Luo J, et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer. Clin Cancer Res. 2017;23:4055-4065.
ClinicalTrials.gov. A phase II randomized study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in post-menopausal women with estrogen-receptor positive primary breast cancer. https://clinicaltrials.gov/ct2/show/NCT02296801. Accessed 25 August 2018.
Martin M, Hurvitz SA, Chan D, et al. Final results of NeoMONARCH: a phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC). In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Cancer Res. 2018;78(suppl). Abstract nr PD5-01.
ClinicalTrials.gov. Neadjuvant multi-agent chemotherapy or letrozole plus ribociclib in luminal B/HER2-negative breast cancer (CORALLEEN). https://clinicaltrials.gov/ct2/show/NCT03248427. Accessed August 25, 2018.
ClinicalTrials.gov. Letrozole plus ribociclib or placebo as neo-adjuvant therapy in ER-positive, HER2-negative early breast cancer (FELINE). https://clinicaltrials.gov/ct2/show/NCT02712723. Accessed August 25, 2018.
ClinicalTrials.gov. Palbociclib collaborative adjuvant study: a randomized phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 (HER2)-negative early breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02513394 Accessed 25 August 2018.
ClinicalTrials.gov. Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy "PENELOPEB." https://clinicaltrials.gov/ct2/show/NCT01864746. Accessed August 25, 2018.
ClinicalTrials.gov. Endocrine therapy with or without abemaciclib (LY2835219) following surgery in participants with breast cancer (monarchE). https://clinicaltrials.gov/ct2/show/NCT03155997 Accessed August 25, 2018.
Rastogi P, Toi M, Harbeck N, et al. MonarchE: a randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2- breast cancer. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Cancer Res. 2018;78(suppl). Abstract OT3-05-05.
TRIO Awarded NATALEE Study, Largest Single Phase III Breast Cancer Clinical Trial in its History. http://www.globenewswire.com/news-release/2018/07/09/1534927/0/en/TRIO-Awarded-NATALEE-Study-Largest-Single-Phase-III-Breast-Cancer-Clinical-Trial-in-its-History.html. Accessed September 19, 2018.
Finn R, Hurvitz S, Allison M, et al. Phase I study of PD 0332991, a novel, oral, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole, for first-line treatment of metastatic post-menopausal, estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Cancer Res. 2009;69:5069-5069.
US Food and Drug Administration. Palbociclib (IBRANCE capsules). Updated February 22, 2016. www.fda.gov/drugs/informationondrugs/approveddrugs/ucm487080.htm . Accessed August 6, 2018.
US Food and Drug Administration. Ribociclib (Kisqali). Updated March 14, 2017. www.fda.gov/drugs/informationondrugs/approveddrugs/ucm546438.htm . Accessed August 6, 2018.
US Food and Drug Administration. FDA approves abemaciclib for HR-positive, HER2-negative breast cancer. Updated September 28, 2017. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm578081.htm. Accessed August 6, 2018.
US Food and Drug Administration. Metastatic breast cancer. Updated February 26, 2018. www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm598404.htm. Accessed August 6, 2018.
IBRANCE® [package insert]. New York, NY: Pfizer Inc; 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf
KISQALI® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf
VERZENIO® [package insert]. Indianapolis, IN: Eli Lilly and Company; September 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716s000lbl.pdf.
Pfizer Announces Overall Survival Results From Phase 3 PALOMA-3 Trial of IBRANCE® (palbociclib) in HR+, HER2- Metastatic Breast Cancer. https://press.pfizer.com/press-release/pfizer-announces-overall-survival-results-phase-3-paloma-3-trial-ibrance-palbociclib-h. Accessed August 6, 2018.
Spring LM, Zangardi ML, Moy B, et al. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist. 2017;22:1039-1048.
Diéras V, Harbeck N, Joyet AA, et al. PALOMA-2: neutropenia patterns in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative first-line advanced breast cancer receiving palbociclib plus letrozole. Poster presented at: 42nd Congress of the European Society for Medical Oncology (ESMO), 2017; Spain. Poster 4016.
Saturni S, Bellini F, Braido F, et al. Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther. 2014;27:129-138.
Zuidgeest MGP, Goetz I, Groenwold RHH, et al, GetReal Work Package 3. Series: pragmatic trials and real world evidence: paper 1. Introduction. J Clin Epidemiol. 2017;88:7-13.
Kish JK, Ward MA, Garofalo D, et al. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res. 2018;20:37.
McRoy L, Mardekian J, Trocio J. Real-world clinical outcomes in patients treated with first-line palbociclib in combination endocrine partner at 2 years postapproval. Poster presented at: 35th Annual Miami Breast Cancer Conference (MBCC); March 8-11, 2018; Miami Beach, FL. Poster 630.
Mitra D, Taylor-Stokes G, Waller J, et al. Real world treatment clinical outcomes associated with palbociclib combination therapy in the United States: results from the IRIS study. Poster presented at: 35th Annual Miami Breast Cancer Conference (MBCC); March 8-11, 2018; Miami Beach, FL. Poster 596.
Taylor-Stokes G, Waller J, Mitra D, et al. Real world treatment patterns and clinical outcomes associated with palbociclib combination therapy in Argentina: results from the IRIS study. J Clin Oncol. 2018;36(suppl):e13026-e13026.
Eziokwu AS, Varella L, Kruse ML, et al. Real world clinical outcomes of palbociclib in hormone receptor positive (HR+) metastatic breast cancer (MBC) patients. J Clin Oncol. 2018;36:(suppl): e13034-e13034.
Rugo HS, Diéras V, Gelmon KA, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018;29:888-894.
Turner NC, Finn RS, Martin M, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol. 2018;29:669-680.
Darden C, Mitra D, McSorley D et al. Patient-reported treatment satisfaction among women receiving palbociclib combination therapies for HR+/HER2- advanced or metastatic breast cancer in the United States. Poster presented at: 35th Annual Miami Breast Cancer Conference (MBCC); March 8-11, 2018; Miami Beach, FL. Poster 598.
Watson GA, Deac O, Aslam R et al. A real-world experience of palbociclib-induced adverse events in women with HR-positive/Her2-negative metastatic breast cancer. J Clin Oncol. 2018;36(suppl):e13061-e13061.
Goldschmidt D, Dalal AA, Romdhani H, et al. Current treatment patterns among postmenopausal women with HR+/HER2- metastatic breast cancer in US community oncology practices: an observational study. Adv Ther. 2018;35:482-493.
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
Pan H, Gray R, Braybrooke J, et al; EBCTCG. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836-1846.
O'Sullivan CC. Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer: the emerging role of CDK 4/6 inhibitors. Int J Cancer Clin Res. 2015;2.
Witzel I, Müller V. The role of CDK 4/6 inhibitors in breast cancer treatment. Breast Care. 2016;11:165-166.
Ibrance® (palbociclib) Receives Approval in European Union for the Treatment of Women With HR+/HER2- Metastatic Breast Cancer. https://www.pfizer.com/news/press-release/press-release-detail/ibrance_palbociclib_receives_approval_in_european_union_for_the_treatment_of_women_with_hr_her2_metastatic_breast_cancer. Accessed August 6, 2018.
Novartis Kisqali® (ribociclib) Receives EU Approval as First-Line Treatment for HR+/HER2- Locally Advanced or Metastatic Breast Cancer in Combination With Any Aromatase Inhibitor. https://novartis.gcs-web.com/Novartis-Kisqali-ribociclib-receives-EU-approval-as-first-line-treatment-for-HR%25252B/HER2. Accessed August 6, 2018.
CHMP Summary Positive Opinion Verzenios. https://www.ema.europa.eu/documents/smop-initial/chmp-summary-positive-opinion-verzenios_en.pdf Accessed October 7, 2018.
Abraham J, Coleman R, Elias A, et al; Breast Cancer Therapy Expert Group (BCTEG). Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Res Treat. 2018;171:11-20.
Laderian B, Fojo T. CDK 4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib. Semin Oncol. 2017;44:395-403.
Di Leo A, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer. Ann Oncol. 2017;28(suppl):v605-v649.
Pfizer Announces Overall Survival Results From Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer. https://press.pfizer.com/press-release/pfizer-announces-overall-survival-results-phase-3-paloma-3-trial-ibrance-palbociclib-h. Accessed August 6, 2018.
Malorni L, Curigliano G, Minisini AM, et al. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Ann Oncol. 2018. [Epub ahead of print]
Wardell SE, Ellis MJ, Alley HM. Efficacy of SERD/SERM hybrid-CDK 4/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer. Clin Cancer Res. 2015;21:5121-5130.
ClinicalTrials.gov. Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer (PARSIFAL). Available from: https://clinicaltrials.gov/ct2/show/NCT02491983. Accessed September 21 2018.
ClinicalTrials.gov. Endocrine Therapy Plus CDK 4/6 in First or Second Line for Hormone Receptor Positive Advanced Breast Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT03425838. Accessed September 21 2018.
European Medicines Agency. Summary of Product Characteristics. IBRANCE. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003853/WC500217196.pdf. Accessed August 21 2018.
European Medicines Agency. Summary of product characteristics. KISQALI. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004213/WC500233997.pdf. Accessed August 21 2018.
Azim HA Jr, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16:427,014-0427-5.
Sheridan W, Scott T, Caroline S, et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? Breast Cancer Res Treat. 2014;147:617-629.
Anders CK, Johnson R, Litton J, et al. Breast cancer before age 40 years. Semin Oncol. 2009;36:237-249.
Paluch-Shimon S, Pagani O, Partridge AH, et al. Second international consensus guidelines for breast cancer in young women (BCY2). Breast. 2016;26:87-99.
Colleoni M. Debate: the biology of breast cancer in young women is unique. Oncologist. 2013;18:e13-e15.
Surakasula A, Nagarjunapu GC, Raghavaiah KV. A comparative study of pre- and post-menopausal breast cancer: risk factors, presentation, characteristics and management. J Res Pharm Pract. 2014;3:12-18.
Bardia A, Hurvitz S. Targeted therapy for premenopausal women with HR+, HER2- advanced breast cancer: focus on special considerations and latest advances. Clin Cancer Res. 2018. pii:clincanres.0162.2018. [Epub ahead of print]
Rugo HS, Turner NC, Finn RS, et al. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018;101:123-133.
ClinicalTrials.gov. Adjuvant ribociclib with endocrine therapy in hormone receptor+/HER2- high risk early breast cancer (EarLEE-1). Accessed August 25, 2018.

CPD

CDK 4/6 Inhibitors in Practice: Expert Insights

Authors: Stephen R.D. Johnston, PhD, FRCP; Richard Finn, MD; Giuseppe Curigliano, MD, PhD
CPD Released: 11/1/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/1/2019, 11:59 PM EST

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically oncologists involved in the treatment of patients with breast cancer.

The goal of this activity is to improve physicians' understanding regarding the treatment and management of patients with hormone receptor (HR)-positive, HER2-negative breast cancer.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Latest clinical and biomarker data supporting use of CDK 4/6 inhibitors for treatment of advanced HR-positive, HER2-negative breast cancer
- Latest clinical data regarding the use of CDK 4/6 inhibitors in real-world practice
Have greater competence related to
- Optimal selection and application of CDK 4/6 inhibitors in clinical practice

Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Giuseppe Curigliano, MD, PhD

Professor
University of Milano
Director
Instituto Europeo di Oncologia
Milan, Italy

Disclosures

Disclosure: Giuseppe Curigliano, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Pfizer Inc.; Roche
Served as a speaker or a member of a speakers bureau for: Pfizer Inc.; Roche

Richard Finn, MD

Associate Professor of Medicine
Geffen School of Medicine
University of California Los Angeles
Los Angeles, California, United States

Disclosures

Disclosure: Richard S. Finn, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare; Bristol-Myers Squibb Company; Eisai Inc.; Eli Lilly and Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.

Stephen R.D. Johnston, PhD, FRCP

Professor of Breast Cancer Medicine
Royal Marsden Hospital
London, England, United Kingdom

Disclosures

Disclosure: Stephen R.D. Johnston, MA, PhD, FRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Pfizer Inc.
Received grants for clinical research from: Pfizer Inc.; Puma

Steering Committee

Nadia Harbeck, MD, PhD

Professor
Breast Center
Department of Obstetrics and Gynecology
University of Munich (LMU)
Munich, Germany

Disclosures

Disclosure: Nadia Harbeck, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Pfizer Inc.

Javier Cortés, MD, PhD

Head
Breast Cancer and Gynecological Tumours
Ramón y Cajal University Hospital
Oncology Department
Madrid, Spain
Clinical Investigator
Breast Cancer Research Program
Vall d'Hebron Institute of Oncology
Barcelona, Spain

Disclosures

Disclosure: Javier Cortés, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Biothera Pharmaceuticals, Inc.; Celgene Corporation; Cellestia Biotech; Roche
Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche

Angelo Di Leo, MD, PhD

Head
Medical Oncology Unit
Chair
Oncology Department
"Sandro Pitigliani" Medical Oncology Unit - Department of Oncology
Hospital of Prato
Istituto Toscano Tumori
Prato, Italy

Disclosures

Disclosure: Angelo Di Leo, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Corporation; Celgene Corporation; Eisai Co., Ltd; Genomic Health; Ipsen; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pierre Fabre; Roche

Stephen R.D. Johnston, PhD, FRCP

Disclosures

As listed above.

Xavier Pivot, MD, PhD

Professor
J Minjoz University Hospital
Besancon, France

Disclosures

Disclosure: Xavier Pivot, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Roche
Served as a speaker or a member of a speaker's bureau for: Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Roche

Sunil Verma, MD, MSEd, FRCPC

Professor
Department of Oncology
Cumming School of Medicine
University of Calgary
Calgary, Alberta, Canada

Disclosures

Disclosure: Sunil Verma, MD, MSEd, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche

Editors

Deborah Middleton, MS

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

Racquel N. Cooper, PhD

Medical Writer & Translator

Disclosures

Disclosure: Racquel N. Cooper, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Nafeez Zawahir, MD

CME Clinical Director

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.75 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

CDK 4/6 Inhibitors in Practice: Expert Insights

Authors: Stephen R.D. Johnston, PhD, FRCP; Richard Finn, MD; Giuseppe Curigliano, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 11/1/2018

Valid for credit through: 11/1/2019, 11:59 PM EST

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

Section 1. Biomarkers of Efficacy and Resistance to CDK 4/6 Inhibitors: An Update

Dr Johnston discusses biomarker data and the impact they may have on treatment selection when using CDK 4/6 inhibitors.
Stephen R.D. Johnston, PhD, FRCP

Section 2. CDK 4/6 Inhibitors in Practice: Evidence From the Real World

Dr Finn explores evidence supporting the use of CDK 4/6 inhibitors in real-world clinical practice.
Richard Finn, MD

Section 3. Application of CDK 4/6 Inhibitors: Insights From Clinical Practice and Practical Considerations

Dr Curigliano discusses aspects of clinical decision-making in selecting a CDK 4/6 inhibitor in clinical practice.
Giuseppe Curigliano, MD, PhD

Page 1 of 4

Section 1. Biomarkers of Efficacy and Resistance to CDK 4/6 Inhibitors: An Update

CPD Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the European Medicines Agency for use in Europe and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Faculty

Giuseppe Curigliano, MD, PhD

Richard Finn, MD

Stephen R.D. Johnston, PhD, FRCP

Steering Committee

Nadia Harbeck, MD, PhD

Javier Cortés, MD, PhD

Angelo Di Leo, MD, PhD

Stephen R.D. Johnston, PhD, FRCP

Xavier Pivot, MD, PhD

Sunil Verma, MD, MSEd, FRCPC

Editors

Deborah Middleton, MS

Racquel N. Cooper, PhD

Content Reviewer

Nafeez Zawahir, MD

CPD

CDK 4/6 Inhibitors in Practice: Expert Insights

Target Audience and Goal Statement

Disclosures

Faculty

Giuseppe Curigliano, MD, PhD

Richard Finn, MD

Stephen R.D. Johnston, PhD, FRCP

Steering Committee

Nadia Harbeck, MD, PhD

Javier Cortés, MD, PhD

Angelo Di Leo, MD, PhD

Stephen R.D. Johnston, PhD, FRCP

Xavier Pivot, MD, PhD

Sunil Verma, MD, MSEd, FRCPC

Editors

Deborah Middleton, MS

Racquel N. Cooper, PhD

Content Reviewer

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

CDK 4/6 Inhibitors in Practice: Expert Insights

Contents of This CPD Activity